Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Docetaxel

- PMLiVE

Novartis scores but Roche misses in melanoma trials

Phase III trial combo success for Tafinlar/Mekinist “unprecedented”

Roche Basel Switzerland

UK is first to receive Roche’s rare lung cancer drug

Alecensa made available under MHRA's early access scheme

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

Roche Basel Switzerland

Roche claims its own CAR-T first with orphan drug Actemra

Comes as FDA approves the first CAR-T therapy from Novartis

Roche Basel Switzerland

Roche wins FDA priority review for haemophilia A drug

Emicizumab prophylaxis could be approved early next year

- PMLiVE

Novartis claims EU approval for breast cancer drug Kisqali

Firm's CDK4/6 inhibitor can now challenge Pfizer's Ibrance in Europe

- PMLiVE

Biocon backs away from biosimilar filings in Europe

EMA asks biotech to withdraw Herceptin and Neulasta biosimilar filings

Roche Basel Switzerland

Roche out-licenses lebrikizumab rights to Dermira

Swiss drug maker stands to receive $80m upfront for the drug

Roche Basel Switzerland

Ocrevus off to a flying start as Roche raises 2017 forecasts

New multiple sclerosis drug posts positive results in first quarter

- PMLiVE

NICE backs Cancer Drugs Fund support for Roche’s Gazyvaro

Lymphoma treatment will be used in conjunction with chemotherapy

- PMLiVE

CHMP backs three immuno-oncology drugs for solid tumours

Roche, MSD and Merck/Pfizer are all on course for new European approvals later this year

- PMLiVE

FDA panel backs Avastin and Herceptin biosimilars

A decision from the US regulator is expected in September

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links